MARTIN REIDINGER, District Judge.
This case is on remand from the MDL-875 in the Eastern District of Pennsylvania. While the case was pending before the MDL Court, the Defendant Crane Co. filed its Rule 26(a)(1) Initial Disclosures which identified Dr. Oury and other individuals as potential lay and expert witnesses to this action. Pursuant to the scheduling order issued by the MDL Court on February 28, 2013, all Defendants were required to submit and endorse their expert reports by May 30, 2013.
Prior to May 30, 2013, Crane Co., along with several other Defendants in this case, including Trane U.S. and Ingersoll-Rand, retained Dr. Oury as an expert witness in this case. [
On May 30, 2013, Crane Co. submitted its Rule 26(a)(1) disclosures which listed Dr. Oury as a potential witness. [
Following the remand of this case, on November 26, 2013, counsel for the parties conducted a telephone conference to discuss the status report to be submitted to the Court. During that telephone conference, counsel for Crane Co. notified Plaintiff's counsel that Crane Co. intended to rely on Dr. Oury's expert opinion in this case. This motion followed.
Rule 37(c) of the Federal Rules of Civil Procedure states that "[i]f a party fails to provide information or identify a witness as required by Rule 26(a) or (e), the party is not allowed to use that information or witness to supply evidence on a motion, at a hearing, or at trial, unless the failure was substantially justified or harmless." Fed. R. Civ. P. 37(c)(1). The Court has "broad discretion" to determine whether a nondisclosure of evidence is substantially justified or harmless.
The Fourth Circuit has stated the following test for determining whether a party's nondisclosure is substantially justified or harmless:
An analysis of the five factors identified by the Fourth Circuit in Southern States leads the Court to conclude that Crane Co.'s omission in listing Dr. Oury as an expert witness was harmless. First, Trane U.S. and Ingersoll-Rand both timely identified Dr. Oury and provided the Plaintiff with a copy of his opinion for this case on May 30, 2013. At the same time, Crane Co. identified Dr. Oury as a potential expert witness in its Rule 26(a)(1) disclosures. Further, it should be noted that Dr. Oury's report is not specific to any particular defendant and is equally applicable to the defendants which explicitly disclosed him and to Crane Co. Accordingly, Plaintiff cannot claim surprise by the contents of Dr. Oury's opinion.
With respect to the second factor, any prejudice to the Plaintiff by Crane Co.'s delayed disclosure of this expert witness can easily be cured. This matter is currently scheduled for trial during the May 2013 trial term. Thus, the Plaintiff has ample opportunity to depose this witness prior to the trial of this matter. Further, allowing Dr. Oury to testify would have no effect or disruption on the trial proceedings in this case, thereby satisfying the third
With respect to the fourth factor of the Southern States test, Dr. Oury's testimony appears to be highly relevant to Crane Co.'s defenses, as it relates directly to the issue of whether products such as those manufactured by Crane Co. could actually have caused the Decedent's injury. As causation is an essential element of Plaintiff's North Carolina negligence and products liability claims, Dr. Oury's report and testimony at trial appears to be central to Crane Co.'s defenses.
The final factor identified in
Upon weighing the